Selepressin and Arginine Vasopressin Do Not Display Cardiovascular Risk in Atherosclerotic Rabbit

Area of Science:

• Cardiovascular Pharmacology
• Sepsis Research

Background:

• Septic shock has high mortality, often treated with arginine vasopressin (AVP) analogs.
• Clinical use of AVP and analogs is limited in patients with comorbidities due to safety concerns.
• Selepressin, a selective V1A agonist, was developed to minimize V2 receptor side effects.

Purpose of the Study:

• To investigate the cardiovascular safety of selepressin, AVP, and norepinephrine.
• To compare vasopressor effects in early-stage atherosclerosis models.

Main Methods:

• Atherosclerosis was induced in New Zealand White rabbits with a cholesterol-rich diet.
• Selepressin, AVP, or norepinephrine were administered via intravenous infusion.
• Cardiovascular responses were assessed in both atherosclerotic and non-atherosclerotic rabbits.

Main Results:

• Selepressin and AVP caused dose-dependent increases in arterial pressure with decreased heart rate and aortic blood flow.
• Norepinephrine increased arterial pressure, heart rate, and aortic blood flow.
• No significant differences in vasopressor response were observed between atherosclerotic and non-atherosclerotic rabbits.

Conclusions:

• Selepressin and AVP did not demonstrate significant cardiovascular risk in early-stage atherosclerosis.
• Further research with advanced atherosclerosis and septic shock models is warranted.
• Findings suggest potential safety for selepressin in septic shock patients with comorbidities.